NEOMED RESEARCH CORPORATION (EIN 341919613) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1999

Legal Domicile

Principal Officer

MARY TAYLOR

Phone

3303256369

Tax Period

2022-07-01 to 2023-06-30

NEOMED RESEARCH CORPORATION, founded in 1999, is a small nonprofit in the Medical Research sector that reported $152K in total revenue in fiscal year 2022. Revenue decreased 6% compared to the prior year. The organization ran a surplus of $75K, a strong 49% operating margin.

Mission

THE CORPORATION SHALL BE OPERATED EXCLUSIVELY FOR THE SCIENTIFIC PURPOSES AS WILL, IN THE ABSOLUTE AND UNCONTROLLED DISCRETION OF THE BOARD OF TRUSTEES, MOST EFFECTIVELY ASSIST AND PROMOTE THE CORPORATION PURPOSES. THE PURPOSES FOR WHICH THE CORPORATION IS TO BE FORMED ARE EXCLUSIVELY TO: A. OBTAIN SCIENTIFIC INFORMATION BENEFICIAL TO THE PUBLIC BY JOINTLY SPONSORING, CONDUCTING, AND ADMINISTERING SCIENTIFIC RESEARCH WITHIN NEOMED; B. FUND SCIENTIFIC RESEARCH AND STUDY CONDUCTED BY STUDENTS AND FACULTY AT NEOMED TO ENHANCE THE QUALITY OF LIFE AND DEVELOP SCIENTIFIC AND TECHNOLOGICAL ADVANCEMENTS FOR THE BENEFIT OF THE PUBLIC; C. MAKE AVAILABLE FOR THE PUBLIC USE THE RESULTS AND FINDINGS OF SCIENTIFIC RESEARCH SPONSORED OR CONDUCTED BY THE CORPORATION AND FUNDING AND CONDUCTING WITH NEOMED WORKSHOPS, SEMINARS, AND SYMPOSIA ON SCIENTIFIC DEVELOPMENTS, TECHNIQUES, AND STUDIES; D. ADVANCE SCIENTIFIC RESEARCH AND FACILITATING THE TRANSFER OF TECHNOLOGY FROM THE LABORATORY TO PUBLIC USE BY, AMONG OTHER ACTIVITIES, MAKING APPLICATIONS FOR AND OBTAINING PATENTS, PATENT RIGHTS, TRADEMARKS, AND COPYRIGHTS FOR DISCOVERIES AND INVENTIONS BY STUDENTS OR FACULTY AT NEOMED AND BY LICENSING SUCH PATENTS, TRADEMARKS, AND COPYRIGHTS SO THAT THE PUBLIC ULTIMATELY MAY BENEFIT FROM SUCH DISCOVERIES AND INVENTIONS; E. ACCEPT GRANTS, EQUITIES AND OTHER THINGS OF VALUE IN SUPPORT OF RESEARCH AND INTELLECTUAL PROPERTY DEVELOPMENT; F. USE MANAGE, ADMINISTER, APPLY, INVEST AND REINVEST THE PRINCIPAL AND INCOME RECEIVED BY THE CORPORATION FOR THE SUPPORT OF RESEARCH AND INTELLECTUAL PROPERTY DEVELOPMENT AT NEOMED; G. LEND, INVEST, OR OTHERWISE APPLY FUNDS OF THE CORPORATION IN SUPPORT OF ANY PURPOSE, ACTIVITY OR ENTERPRISE THAT RELATES TO AND CONTRIBUTES TO, OR ADVANCES THE PURPOSE OF THE CORPORATION, PROVIDED SUCH PURPOSE IS CONSISTENT WITH ITS EXEMPT AND FAVORED STATUS UNDER THE TAX LAWS AND ALL OTHER SUBSTANTIVE LAW; H. DO WHATEVER IS DEEMED NECESSARY, USEFUL, ADVISABLE OR CONDUCTIVE, DIRECTLY OR INDIRECTLY, TO CARRY OUT ANY OF THE PURPOSES OF THE CORPORATION, INCLUDING THE EXERCISE OF ALL OTHER AUTHORITY ENJOYED BY CORPORATIONS GENERALLY BY VIRTUE OF THE PROVISIONS OF THE OHIO NON-PROFIT CORPORATION LAW.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2022)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $151,563

Investment Income $483

Other Revenue $0

TOTAL REVENUE $152,046

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $58,550

Other Expenses $77,456

TOTAL EXPENSES $77,456

Year-over-Year Comparison

	2022	2021	Change
Revenue	$152,046	$161,660	-0.1%
Expenses	$77,456	$154,925	-0.5%
Net Income	$74,590	$6,735	+10.1%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,169,821

Total Directors

$2,128,410

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RICHARD KASMER	VICE CHAIR	1.00	Officer Director	$0	$0	$358,863
MARY TAYLOR	TREASURER	1.00	Officer Director	$0	$0	$257,284
MARIA SCHIMER	SECRETARY	1.00	Officer Director	$0	$0	$283,760
REBECCA GERMAN	INTERIM CHAIR	1.00	Officer Director	$0	$0	$269,914
JOHN T LANGELL	DIRECTOR	1.00	Director	$0	$0	$958,589

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	No data	No data	No data	No data
2023	$152,046	$77,456	$778,835	$74,590
2022	$161,660	$154,925	$724,521	$6,735
2021	$134,570	$194,020	$773,131	$-59,450
2020	$123,265	$145,662	$817,985	$-22,397
2019	$118,985	$106,774	$779,436	$12,211
2018	$282,577	$219,976	$785,027	$62,601

NEOMED RESEARCH CORPORATION